Sartorius Stedim grew third-quarter sales 7.4% in constant currencies before tariff compensation to customers. Underlying EBITDA margin was 31.1% versus 31.3% a year earlier, which was in line with company-compiled consensus. Management confirmed full-year guidance.
SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.
The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Price/Earnings (Normalized) | 49.99 | 17.91 | 29.29 |
Price/Book Value | 4.93 | 2.08 | 6.80 |
Price/Sales | 7.05 | 2.97 | 6.83 |
Price/Cash Flow | 33.34 | 13.80 | 26.53 |
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Quick Ratio | 0.50 | 0.99 | 1.41 |
Current Ratio | 1.22 | 1.69 | 2.05 |
Interest Coverage | 5.30 | 7.22 | 16.08 |
|
Metric
|
DIM
|
MRK
|
A
|
|---|---|---|---|
Return on Assets (Normalized) | 5.74% | 4.75% | 13.27% |
Return on Equity (Normalized) | 11.02% | 8.32% | 24.92% |
Return on Invested Capital (Normalized) | 7.90% | 6.65% | 16.95% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| LOCK|%?t@PB! | LOCK|bqP | $158B | |||
| Becton Dickinson & Co
BDX
| LOCK|h<$ | LOCK|&TB<# | $53B | |||
| ResMed Inc
RMD
| LOCK|fx$Qkv>P | LOCK|!dL# | $35B | |||
| Alcon Inc
ALC
| LOCK|v$v&XMw | LOCK|rsPy | $34B | |||
| Medline Inc Ordinary Shares - Class A
MDLN
| LOCK|@@?>cL | LOCK|H$P? | $28B | |||
| West Pharmaceutical Services Inc
WST
| LOCK|Ls?^#@n | LOCK|$Sq | $28B | |||
| Solventum Corp
SOLV
| LOCK|f&q<sG | LOCK|^M | $14B | |||
| Baxter International Inc
BAX
| LOCK|?y | LOCK|pZ#R | $13B | |||
| The Cooper Companies Inc
COO
| LOCK|z>qCF^< | LOCK|>Yv! | $11B | |||
| Repligen Corp
RGEN
| LOCK|hWjCbR^ | LOCK|<RFs? | $11B |
United States